Skip to main content

Articles

Page 3 of 33

  1. The over-activation of adenosine A2A receptors (A2AR) is closely implicated in cognitive impairments of Alzheimer's disease (AD). Growing evidence shows that A2AR blockade possesses neuroprotective effects on AD....

    Authors: Qi Ji, Yang Yang, Yun Xiong, Ying-Jie Zhang, Jun Jiang, Li-Ping Zhou, Xiao-Hui Du, Chun-Xiang Wang and Zhi-Ru Zhu
    Citation: Alzheimer's Research & Therapy 2023 15:187
  2. Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membran...

    Authors: Julie Goossens, Alba Cervantes González, Nele Dewit, Laia Lidón, Juan Fortea, Daniel Alcolea, Alberto Lleó, Olivia Belbin and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:186
  3. Alzheimer's disease (AD) is a neurodegenerative disease and the main cause for dementia. The irreversible neurodegeneration leads to a gradual loss of brain function characterized predominantly by memory loss....

    Authors: Xiaozhu Liu, Samuel Halvorsen, Nathan Blanke, Margaret Downs, Thor D. Stein, Irving J. Bigio, Joseph Zaia and Yanhang Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:185
  4. In MAPT (Multidomain Alzheimer Preventive Trial), a cognitive effect of multidomain intervention (MI) was showed in non-demented subjects with positive amyloid PET. However, screening eligible patients for mul...

    Authors: Julien Delrieu, Bruno Vellas, Sophie Guyonnet, Christelle Cantet, Vitaliy Ovod, Yan Li, James Bollinger, Randall Bateman and Sandrine Andrieu
    Citation: Alzheimer's Research & Therapy 2023 15:183
  5. To enable successful inclusion of electroencephalography (EEG) outcome measures in Alzheimer’s disease (AD) clinical trials, we retrospectively mapped the progression of resting-state EEG measures over time in...

    Authors: Elliz P. Scheijbeler, Willem de Haan, Cornelis J. Stam, Jos W. R. Twisk and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2023 15:182
  6. APOE genotype is the greatest genetic risk factor for sporadic Alzheimer’s disease (AD). APOE4 increases AD risk up to 12-fold compared to APOE3, an effect that is greater in females. Evidence suggests that one-w...

    Authors: Deebika Balu, Ana C. Valencia-Olvera, Austin Nguyen, Mehul Patnam, Jason York, Francesco Peri, Frank Neumann, Mary Jo LaDu and Leon M. Tai
    Citation: Alzheimer's Research & Therapy 2023 15:181
  7. Alzheimer’s disease involves accumulating amyloid (A) and tau (T) pathology, and progressive neurodegeneration (N), leading to the development of the AD clinical syndrome. While several markers of N have been ...

    Authors: Rigina L. Gallagher, Rebecca Langhough Koscik, Jason F. Moody, Nicholas M. Vogt, Nagesh Adluru, Steven R. Kecskemeti, Carol A. Van Hulle, Nathaniel A. Chin, Sanjay Asthana, Gwendlyn Kollmorgen, Ivonne Suridjan, Cynthia M. Carlsson, Sterling C. Johnson, Douglas C. Dean III, Henrik Zetterberg, Kaj Blennow…
    Citation: Alzheimer's Research & Therapy 2023 15:180
  8. Current treatments for Alzheimer’s disease (AD) have largely failed to yield significant therapeutic benefits. Novel approaches are desperately needed to help address this immense public health issue. Data sug...

    Authors: Nancy R. Stallings, Melissa A. O’Neal, Jie Hu, Zhong-Jian Shen and James S. Malter
    Citation: Alzheimer's Research & Therapy 2023 15:179
  9. The effect of amyloid-β (Aβ) on cognitive impairment in patients with small subcortical infarction remains controversial, although a growing body of evidence shows a substantial overlap between Alzheimer’s dis...

    Authors: Sung Hoon Kang, Minwoong Kang, Jung Hoon Han, Eun Seong Lee, Keon-Joo Lee, Su Jin Chung, Sang-Il Suh, Seong-Beom Koh, Jae Seon Eo, Chi Kyung Kim and Kyungmi Oh
    Citation: Alzheimer's Research & Therapy 2023 15:178
  10. Authors: Patricia Diaz‑Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:177

    The original article was published in Alzheimer's Research & Therapy 2023 15:117

  11. Mild cognitive impairment (MCI) is often considered an early stage of dementia, with estimated rates of progression to dementia up to 80–90% after approximately 6 years from the initial diagnosis. Diagnosis of...

    Authors: Kevin Blanco, Stefanny Salcidua, Paulina Orellana, Tania Sauma-Pérez, Tomás León, Lorena Cecilia López Steinmetz, Agustín Ibañez, Claudia Duran-Aniotz and Rolando de la Cruz
    Citation: Alzheimer's Research & Therapy 2023 15:176
  12. Development of in vivo biomarkers has shifted the diagnosis of Alzheimer’s disease (AD) from the later dementia stages of disease towards the earlier stages and has introduced the potential for pre-symptomatic...

    Authors: Bruno Dubois, Christine A. F. von Arnim, Nerida Burnie, Sasha Bozeat and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2023 15:175
  13. Soluble amyloid-beta oligomers (Aβo) begin to accumulate in the human brain one to two decades before a clinical diagnosis of Alzheimer’s disease (AD). The literature supports that soluble Aβo are implicated i...

    Authors: Audrey Hector, Chloé Provost, Benoît Delignat-Lavaud, Khadija Bouamira, Chahinez-Anissa Menaouar, Valérie Mongrain and Jonathan Brouillette
    Citation: Alzheimer's Research & Therapy 2023 15:174
  14. It is unknown if fluid biomarkers reflective of brain pathologies are useful in detecting and following a neurodegenerative process in individuals exposed to repetitive head impacts. This study explores the re...

    Authors: Charles Bernick, Guogen Shan, Aaron Ritter, Nicholas J. Ashton, Kaj Blennow, Juan Lantero-Rodriguez, Anniina Snellman and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2023 15:173
  15. Compared to standard neuro-diagnostic techniques, retinal biomarkers provide a probable low-cost and non-invasive alternative for early Alzheimer’s disease (AD) risk screening. We have previously quantified th...

    Authors: Edmund Arthur, Swetha Ravichandran, Peter J. Snyder, Jessica Alber, Jennifer Strenger, Ava K. Bittner, Rima Khankan, Stephanie L. Adams, Nicole M. Putnam, Karin R. Lypka, Juan A. Piantino and Stuart Sinoff
    Citation: Alzheimer's Research & Therapy 2023 15:172
  16. Alterations in mitochondrial DNA (mtDNA) levels have been observed in Alzheimer’s disease and are an area of research that shows promise as a useful biomarker. It is well known that not only are the mitochondr...

    Authors: Isabelle K. Gorham, Robert C. Barber, Harlan P. Jones and Nicole R. Phillips
    Citation: Alzheimer's Research & Therapy 2023 15:171
  17. The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...

    Authors: Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2023 15:170
  18. The first predominant clinical symptoms of dementia with Lewy bodies (DLB) are highly variable; however, the prognosis based on initial predominant symptoms remains poorly understood.

    Authors: Clément Aveneau, David Wallon, Bertrand Degos, Alexandre Obadia, Claire Hourregue, Sarah Benisty, Béatrice Garcin, Julien Dumurgier and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2023 15:169
  19. Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal ...

    Authors: Jeffrey L. Cummings, M. Isabel Gonzalez, Martyn C. Pritchard, Patrick C. May, Leticia M. Toledo-Sherman and Glenn A. Harris
    Citation: Alzheimer's Research & Therapy 2023 15:168
  20. Prevalence of overall cognitive impairment based on each participant’s performance across a neuropsychological battery is challenging; consequently, we define and validate a dichotomous cognitive impairment/no...

    Authors: Megan E. O’Connell, Helena Kadlec, Lauren E. Griffith, Christina Wolfson, Geva Maimon, Vanessa Taler, Susan Kirkland and Parminder Raina
    Citation: Alzheimer's Research & Therapy 2023 15:167
  21. Exposure to repetitive head impacts (RHI) in American football players can lead to cognitive impairment and dementia due to neurodegenerative disease, particularly chronic traumatic encephalopathy (CTE). The p...

    Authors: Robert A. Stern, Diana Trujillo-Rodriguez, Yorghos Tripodis, Surya V. Pulukuri, Michael L. Alosco, Charles H. Adler, Laura J. Balcer, Charles Bernick, Zachary Baucom, Kenneth L. Marek, Michael D. McClean, Keith A. Johnson, Ann C. McKee, Thor D. Stein, Jesse Mez, Joseph N. Palmisano…
    Citation: Alzheimer's Research & Therapy 2023 15:166
  22. There has been increasing interest in cortical microstructure as a complementary and earlier measure of neurodegeneration than macrostructural atrophy, but few papers have related cortical diffusion imaging to...

    Authors: Mario Torso, Gerard R. Ridgway, Michele Valotti, Ian Hardingham and Steven A. Chance
    Citation: Alzheimer's Research & Therapy 2023 15:165
  23. Hyperhomocysteinemia (HHcy) has been linked to development of Alzheimer’s disease (AD) neuropathologically characterized by the accumulation of amyloid β (Aβ). Microglia (MG) play a crucial role in uptake of A...

    Authors: Xianwei Wang, Lu Liu, Xiaohua Jiang, Jason Saredy, Hang Xi, Ramon Cueto, Danni Sigler, Mohsin Khan, Sheng Wu, Yong Ji, Nathaniel W. Snyder, Wenhui Hu, Xiaofeng Yang and Hong Wang
    Citation: Alzheimer's Research & Therapy 2023 15:164
  24. The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate scre...

    Authors: Francisco Martínez-Dubarbie, Armando Guerra-Ruiz, Sara López-García, Carmen Lage, Marta Fernández-Matarrubia, Jon Infante, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Marcos López-Hoyos, Juan Irure-Ventura, Pascual Sánchez-Juan, María Teresa García-Unzueta and Eloy Rodríguez-Rodríguez
    Citation: Alzheimer's Research & Therapy 2023 15:163
  25. Chronic stress and depression are potential risk factors for mild cognitive impairment and dementia, including Alzheimer disease. The aim was to investigate whether any such risk is additive.

    Authors: Johanna Wallensten, Gunnar Ljunggren, Anna Nager, Caroline Wachtler, Nenad Bogdanovic, Predrag Petrovic and Axel C. Carlsson
    Citation: Alzheimer's Research & Therapy 2023 15:161
  26. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13195-021-00769-9.

    Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2023 15:162
  27. Authors: Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Jennifer C. Howell, William T. Hu, Kim Kultima and Henrietta M. Nielsen
    Citation: Alzheimer's Research & Therapy 2023 15:160

    The original article was published in Alzheimer's Research & Therapy 2023 15:119

  28. Although increasing physical activity (PA) has been suggested to prevent and manage cognitive decline and dementia, its economic impact on healthcare systems and society is largely unknown. This study aimed to...

    Authors: Weixin Li, Kun-Woo Rafael Kim, Donglan Zhang, Bian Liu, Christine M. Dengler-Crish, Ming Wen, Lu Shi, Xi Pan, Yian Gu and Yan Li
    Citation: Alzheimer's Research & Therapy 2023 15:159
  29. People with mild cognitive impairment (MCI) experience a loss of cognitive functions, whose mechanism is characterized by aberrant structure‒function (SC-FC) coupling and topological attributes of multiple net...

    Authors: Jingsong Wu, Youze He, Shengxiang Liang, Zhizhen Liu, Jia Huang, Weilin Liu, Jing Tao, Lidian Chen, Chetwyn C. H. Chan and Tatia M. C. Lee
    Citation: Alzheimer's Research & Therapy 2023 15:158
  30. Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences be...

    Authors: Nidhi S. Mundada, Julio C. Rojas, Lawren Vandevrede, Elisabeth H. Thijssen, Leonardo Iaccarino, Obiora C. Okoye, Ranjani Shankar, David N. Soleimani-Meigooni, Argentina L. Lago, Bruce L. Miller, Charlotte E. Teunissen, Hillary Heuer, Howie J. Rosen, Jeffrey L. Dage, William J. Jagust, Gil D. Rabinovici…
    Citation: Alzheimer's Research & Therapy 2023 15:157
  31. Neuron-derived extracellular vesicles (NDEVs) in blood may be used to derive biomarkers for the effects of exercise in Alzheimer’s disease (AD). For this purpose, we studied changes in neuroprotective proteins...

    Authors: Francheska Delgado-Peraza, Carlos Nogueras-Ortiz, Anja Hviid Simonsen, De’Larrian DeAnté Knight, Pamela J. Yao, Edward J. Goetzl, Camilla Steen Jensen, Peter Høgh, Hanne Gottrup, Karsten Vestergaard, Steen Gregers Hasselbalch and Dimitrios Kapogiannis
    Citation: Alzheimer's Research & Therapy 2023 15:156

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:18

  32. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  33. Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few...

    Authors: Shiraz Vered, Alexa S. Beiser, Liron Sulimani, Sharon Sznitman, Mitzi M. Gonzales, Hugo J. Aparicio, Charles DeCarli, Matthew R. Scott, Saptaparni Ghosh, Gil M. Lewitus, David Meiri, Sudha Seshadri and Galit Weinstein
    Citation: Alzheimer's Research & Therapy 2023 15:154
  34. Depression and dementia are both common diseases. Although new cases of depression are more common in younger adults, there is a second peak at the age of 50 years suggesting a different pathological process. ...

    Authors: Lindsey I. Sinclair, Asher Mohr, Mizuki Morisaki, Martin Edmondson, Selina Chan, A. Bone-Connaughton, Gustavo Turecki and Seth Love
    Citation: Alzheimer's Research & Therapy 2023 15:153

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:33

  35. The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of c...

    Authors: Chun Zhou, Yanjun Zhang, Sisi Yang, Ziliang Ye, Qimeng Wu, Mengyi Liu, Panpan He, Yuanyuan Zhang and Xianhui Qin
    Citation: Alzheimer's Research & Therapy 2023 15:152
  36. Rapid-eye movement (REM) sleep highly depends on the activity of cholinergic basal forebrain (BF) neurons and is reduced in Alzheimer’s disease. Here, we investigated the associations between the volume of BF ...

    Authors: Claire André, Marie-Ève Martineau-Dussault, Véronique Daneault, Hélène Blais, Sonia Frenette, Dominique Lorrain, Carol Hudon, Célyne Bastien, Dominique Petit, Alexandre Lafrenière, Cynthia Thompson, Jacques Montplaisir, Nadia Gosselin and Julie Carrier
    Citation: Alzheimer's Research & Therapy 2023 15:151
  37. The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (C...

    Authors: Giuseppe Mario Bentivenga, Simone Baiardi, Andrea Mastrangelo, Corrado Zenesini, Angela Mammana, Barbara Polischi, Sabina Capellari and Piero Parchi
    Citation: Alzheimer's Research & Therapy 2023 15:150
  38. Plasma biomarkers have emerged as promising screening tools for Alzheimer’s disease (AD) because of their potential to detect amyloid β (Aβ) accumulation in the brain. One such candidate is the plasma Aβ42/40 ...

    Authors: Shogyoku Bun, Daisuke Ito, Toshiki Tezuka, Masahito Kubota, Ryo Ueda, Keisuke Takahata, Sho Moriguchi, Shin Kurose, Yuki Momota, Natsumi Suzuki, Ayaka Morimoto, Yuka Hoshino, Morinobu Seki, Yu Mimura, Ryo Shikimoto, Yasuharu Yamamoto…
    Citation: Alzheimer's Research & Therapy 2023 15:149
  39. A minimally invasive blood-based assessment of cognitive function could be a promising screening strategy to identify high-risk groups for the incidence of Alzheimer’s disease.

    Authors: Kanika Mehta, Mohammadreza Mohebbi, Julie A. Pasco, Lana J. Williams, Sophia X. Sui, Ken Walder, Boon Lung Ng and Veer Bala Gupta
    Citation: Alzheimer's Research & Therapy 2023 15:148
  40. Post-stroke cognitive impairment (PSCI) occurs in up to 50% of patients with acute ischemic stroke (AIS). Thus, the prediction of cognitive outcomes in AIS may be useful for treatment decisions. This PSCI coho...

    Authors: Minwoo Lee, Na-Young Yeo, Hyo-Jeong Ahn, Jae-Sung Lim, Yerim Kim, Sang-Hwa Lee, Mi Sun Oh, Byung-Chul Lee, Kyung-Ho Yu and Chulho Kim
    Citation: Alzheimer's Research & Therapy 2023 15:147
  41. Polygenic Risk Scores (PRSs) are summaries of genetic risk alleles for an outcome.

    Authors: Tamar Sofer, Nuzulul Kurniansyah, Einat Granot-Hershkovitz, Matthew O. Goodman, Wassim Tarraf, Iris Broce, Richard B. Lipton, Martha Daviglus, Melissa Lamar, Sylvia Wassertheil-Smoller, Jianwen Cai, Charles S. DeCarli, Hector M. Gonzalez and Myriam Fornage
    Citation: Alzheimer's Research & Therapy 2023 15:146
  42. The Rey Complex Figure Test (RCFT) has been widely used to evaluate the neurocognitive functions in various clinical groups with a broad range of ages. However, despite its usefulness, the scoring method is as...

    Authors: Jun Young Park, Eun Hyun Seo, Hyung-Jun Yoon, Sungho Won and Kun Ho Lee
    Citation: Alzheimer's Research & Therapy 2023 15:145
  43. Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ)42 to detect amyloid pathology, the Aβ42/Aβ40 ratio (amyR) better estimates amyloid load, with higher specificity for Alzheimer’s disease...

    Authors: Caterina Motta, Martina Gaia Di Donna, Chiara Giuseppina Bonomi, Martina Assogna, Agostino Chiaravalloti, Nicola Biagio Mercuri, Giacomo Koch and Alessandro Martorana
    Citation: Alzheimer's Research & Therapy 2023 15:144
  44. Little is known about the associations of midlife- and late life-initiated walking with Alzheimer’s disease (AD)-related cognitive decline in humans. We aimed to investigate whether high-intensity, prolonged, ...

    Authors: Young Min Choe, Guk-Hee Suh, Boung Chul Lee, Ihn-Geun Choi, Hyun Soo Kim, Jong Wan Kim, Jaeuk Hwang, Dahyun Yi and Jee Wook Kim
    Citation: Alzheimer's Research & Therapy 2023 15:143
  45. Studies in animal models of Alzheimer’s disease (AD) have provided valuable insights into the molecular and cellular processes underlying neuronal network dysfunction. Whether and how AD-related neurophysiolog...

    Authors: Fran C. van Heusden, Anne M. van Nifterick, Bryan C. Souza, Arthur S. C. França, Ilse M. Nauta, Cornelis J. Stam, Philip Scheltens, August B. Smit, Alida A. Gouw and Ronald E. van Kesteren
    Citation: Alzheimer's Research & Therapy 2023 15:142
  46. The effects of insulin-like growth factor-1 (IGF-1) deficiency on cognitive decline have been consistently reported in animal studies, but the relationship between IGF-1 and human brain health remains controve...

    Authors: Zhi Cao, Jiahao Min, Qilong Tan, Keyi Si, Hongxi Yang and Chenjie Xu
    Citation: Alzheimer's Research & Therapy 2023 15:140
  47. Associations between kidney function and dementia risk are inconclusive. Chronic kidney disease (CKD) severity is determined by levels of both estimated glomerular filtration rate (eGFR) and the urine albumin ...

    Authors: Tian-Shin Yeh, Lei Clifton, Jennifer A. Collister, Xiaonan Liu, David J. Hunter and Thomas J. Littlejohns
    Citation: Alzheimer's Research & Therapy 2023 15:138